Pomalidomide-based therapy for extramedullary multiple myeloma

References

• Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer. 2019;144(8):1941–1953. doi:10.1002/ijc.31937
   PubMed Web of Science ®Google Scholar
• Kumar SK, Rajkumar V, Kyle RA, et al. Multiple myeloma. Nat Rev Dis Primers. 2017;3:17046. doi:10.1038/nrdp.2017.46
   PubMed Web of Science ®Google Scholar
• Touzeau C, Moreau P. How I treat extramedullary myeloma. Blood. 2016;127(8):971–976. doi:10.1182/blood-2015-07-635383
   PubMed Web of Science ®Google Scholar
• Usmani SZ, Heuck C, Mitchell A, et al. Extramedullary disease portends poor prognosis in multiple myeloma and is over-represented in high-risk disease even in the era of novel agents. Haematologica. 2012;97(11):1761–1767. doi:10.3324/haematol.2012.065698
   PubMed Web of Science ®Google Scholar
• Mangiacavalli S, Pompa A, Ferretti V, et al. The possible role of burden of therapy on the risk of myeloma extramedullary spread. Ann Hematol. 2017;96(1):73–80. doi:10.1007/s00277-016-2847-z
   PubMed Web of Science ®Google Scholar
• Bladé J, Fernández de Larrea C, Rosiñol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol. 2011;29(28):3805–3812. doi:10.1200/jco.2011.34.9290
   PubMed Web of Science ®Google Scholar
• Pour L, Sevcikova S, Greslikova H, et al. Soft-tissue extramedullary multiple myeloma prognosis is significantly worse in comparison to bone-related extramedullary relapse. Haematologica. 2014;99(2):360–364. doi:10.3324/haematol.2013.094409
   PubMed Web of Science ®Google Scholar
• Rosinol L, Beksac M, Zamagni E, et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br J Haematol. 2021;194(3):496–507. doi:10.1111/bjh.17338
   PubMed Web of Science ®Google Scholar
• Weinstock M, Ghobrial IM. Extramedullary multiple myeloma. Leuk Lymphoma. 2013;54(6):1135–1141. doi:10.3109/10428194.2012.740562
   PubMed Web of Science ®Google Scholar
• Pasmantier MW, Azar HA. Extraskeletal spread in multiple plasma cell myeloma. A review of 57 autopsied cases. Cancer. 1969;23(1):167–174. doi:10.1002/1097-0142(196901)23:1<167::aid-cncr2820230122>3.0.co;2-0
   PubMed Web of Science ®Google Scholar
• Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica. 2007;92(1):143–144. doi:10.3324/haematol.10297
   PubMed Web of Science ®Google Scholar
• Cerny J, Fadare O, Hutchinson L, et al. Clinicopathological features of extramedullary recurrence/relapse of multiple myeloma. Eur J Haematol. 2008;81(1):65–69. doi:10.1111/j.1600-0609.2008.01087.x
   PubMed Web of Science ®Google Scholar
• Sevcikova S, Minarik J, Stork M, et al. Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev. 2019;36:32–39. doi:10.1016/j.blre.2019.04.002
   PubMed Web of Science ®Google Scholar
• Perez-Simon JA, Sureda A, Fernandez-Aviles F, et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia. 2006;20(3):542–545. doi:10.1038/sj.leu.2404085
   PubMed Web of Science ®Google Scholar
• Bhutani M, Foureau DM, Atrash S, et al. Extramedullary multiple myeloma. Leukemia. 2020;34(1):1–20. doi:10.1038/s41375-019-0660-0
   PubMed Web of Science ®Google Scholar
• Durie BG, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20(9):1467–1473. doi:10.1038/sj.leu.2404284
   PubMed Web of Science ®Google Scholar
• Kumar SK, Callander NS, Adekola K, et al. Multiple Myeloma, Version 3.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Network. 2020;18(12):1685–1717. doi:10.6004/jnccn.2020.0057
   PubMedGoogle Scholar
• Voorhees PM, Mulkey F, Hassoun H, et al. Alliance A061202. a phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor based therapy: phase I results. Blood. 2015;126(23):375. doi:10.1182/blood.V126.23.375.375
   Google Scholar
• Krishnan AY, Kapoor P, Palmer J, et al. A phase I/II study of ixazomib (Ix) pomalidomide (POM) dexamethasone (DEX) in relapsed refractory (R/R) multiple myeloma: initial results. J Clin Oncol. 2016;34(15_suppl.):8008. doi:10.1200/JCO.2016.34.15_suppl.8008
   Web of Science ®Google Scholar
• Richardson PG, Oriol A, Beksac M, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(6):781–794. doi:10.1016/s1470-2045(19)30152-4
   PubMed Web of Science ®Google Scholar
• Chari A, Suvannasankha A, Fay JW, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma. Blood. 2017;130(8):974–981. doi:10.1182/blood-2017-05-785246
   PubMed Web of Science ®Google Scholar
• Lu YY, Chen JH, Liang JA, et al. 18F-FDG PET or PET/CT for detecting extensive disease in small-cell lung cancer: a systematic review and meta-analysis. Nucl Med Commun. 2014;35(7):697–703. doi:10.1097/MNM.0000000000000122
   PubMed Web of Science ®Google Scholar
• Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol. 2010;21(2):325–330. doi:10.1093/annonc/mdp329
   PubMed Web of Science ®Google Scholar
• Gagelmann N, Eikema DJ, Iacobelli S, et al. Impact of extramedullary disease in patients with newly diagnosed multiple myeloma undergoing autologous stem cell transplantation: a study from the chronic malignancies working party of the EBMT. Haematologica. 2018;103(5):890–897. doi:10.3324/haematol.2017.178434
   PubMed Web of Science ®Google Scholar
• Dingli D, Ailawadhi S, Bergsagel PL, et al. Therapy for relapsed multiple myeloma: guidelines from the mayo stratification for myeloma and risk-adapted therapy. Mayo Clin Proc. 2017;92(4):578–598. doi:10.1016/j.mayocp.2017.01.003
   PubMed Web of Science ®Google Scholar
• Lakshman A, Singh PP, Rajkumar SV, et al. Efficacy of VDT PACE-like regimens in treatment of relapsed/refractory multiple myeloma. Am J Hematol. 2018;93(2):179–186. doi:10.1002/ajh.24954
   PubMed Web of Science ®Google Scholar
• Barlogie B, Anaissie E, van Rhee F, et al. Incorporating bortezomib into upfront treatment for multiple myeloma: early results of total therapy 3. Br J Haematol. 2007;138(2):176–185. doi:10.1111/j.1365-2141.2007.06639.x
   PubMed Web of Science ®Google Scholar
• Muchtar E, Ram R, Raanani P, et al. First line and salvage therapy with total therapy 3-based treatment for multiple myeloma––an extended single center experience. Leuk Res. 2014;38(12):1401–1406. doi:10.1016/j.leukres.2014.06.024
   PubMed Web of Science ®Google Scholar
• Muchtar E, Gatt ME, Rouvio O, et al. Efficacy and safety of salvage therapy using Carfilzomib for relapsed or refractory multiple myeloma patients: a multicentre retrospective observational study. Br J Haematol. 2016;172(1):89–96. doi:10.1111/bjh.13799
   PubMed Web of Science ®Google Scholar
• Laura Rosiñol MTC, Bladé J, Esteve J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica. 2004;89(7):832–836.
   PubMed Web of Science ®Google Scholar
• Short KD, Rajkumar SV, Larson D, et al. Incidence of extramedullary disease in patients with multiple myeloma in the era of novel therapy, and the activity of pomalidomide on extramedullary myeloma. Leukemia. 2011;25(6):906–908. doi:10.1038/leu.2011.29
   PubMed Web of Science ®Google Scholar
• Li J, Shen KN, Huang WR, et al. Autologous stem cell transplant can overcome poor prognosis in patients with multiple myeloma with extramedullary plasmacytoma. Leuk Lymphoma. 2014;55(7):1687–1690. doi:10.3109/10428194.2013.853296
   PubMed Web of Science ®Google Scholar
• Lee SE, Kim JH, Jeon YW, et al. Impact of extramedullary plasmacytomas on outcomes according to treatment approach in newly diagnosed symptomatic multiple myeloma. Ann Hematol. 2015;94(3):445–452. doi:10.1007/s00277-014-2216-8
   PubMed Web of Science ®Google Scholar
• Kumar L, Gogi R, Patel AK, et al. Multiple myeloma with extramedullary disease: impact of autologous stem cell transplantation on outcome. Bone Marrow Transplant. 2017;52(10):1473–1475. doi:10.1038/bmt.2017.165
   PubMed Web of Science ®Google Scholar
• Brudno JN, Maric I, Hartman SD, et al. T cells genetically modified to express an anti–B-cell maturation antigen chimeric antigen receptor cause remissions of poor-prognosis Relapsed Multiple myeloma. J Clin Oncol. 2018;36(22):2267–2280. doi:10.1200/JCO.2018.77.8084
   PubMed Web of Science ®Google Scholar
• Xu J, Chen LJ, Yang SS, et al. Exploratory trial of a biepitopic CAR T-targeting B cell maturation antigen in relapsed/refractory multiple myeloma. Proc Natl Acad Sci USA. 2019;116(19):9543–9551. doi:10.1073/pnas.1819745116
   PubMed Web of Science ®Google Scholar
• Qu X, Chen L, Qiu H, et al. Extramedullary manifestation in multiple myeloma bears high incidence of poor cytogenetic aberration and novel agents resistance. Biomed Res Int. 2015;2015:787809. doi:10.1155/2015/787809
   PubMed Web of Science ®Google Scholar